A Phase 4 interventional study of Ropivacaine and Non steroidal anti-inflammatory drug and opioids in Rib Fractures, sponsored by Zachary Warriner. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Zachary Warriner · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Rib Fractures with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Rib Fractures · United States.
Among the 48 studies in Rib Fractures with a site in United States, this one is the 3rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 17 in phase 4, and was the 35th registered.
126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.
Browse Rib Fractures studies →9 of the 48 studies in Rib Fractures with a site in United States are open now. Recruiting first, the newest first:
Zimmer Biomet · Sites in United States
Ages 18+
Albert Einstein College of Medicine · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–80 · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Rib Fractures studies recruiting now, 9 (64%) set no upper age limit and 1 (7%) stops at 75 or younger; none take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 60 across 92 interventional studies indexed under Rib Fractures.
Median enrollment 36 across the 41 interventional studies, 43 across the 7 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 48 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Zachary Warriner as lead sponsor.
Zachary Warriner has 1 study filed under Rib Fractures — fewer than ten, so there is no comparison to draw.
7 of the studies in Rib Fractures with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT05642026Zachary WarrinerINTERCOSTAL NERVE BLOCK: Efficacy of CINB for Patients With Multiple Rib Fractures | 2027-02-01 |
| NCT06347874University of MinnesotaCryo Rib Fracture Study | 2027-02-13 |
| NCT05748366WellSpan HealthUltrasound Guided Serratus Anterior Plane Block for Rib Fractures | 2027-03-31 |
| NCT07032766Albert Einstein College of MedicineAssessment of Morbidity and Mortality Following Serratus Anterior Plane Block (SAPB) for Unilateral Rib Fractures | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 48 studies in Rib Fractures with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, randomized, non-blinded study comparing CINB plus medical therapy versus standard medical care (non-steroidals and opioids intravenous/oral inpatient and oral outpatient) alone for patients with multiple rib fractures. The objective of this study is to analyze the effect of continuous intercostal nerve block (CINB) in the treatment of patients admitted to the adult trauma service with rib fractures. The effectiveness of CINB as adjunctive treatment will be compared to standard medical therapy involving nonsteroidal and intravenous/oral opioid medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients admitted to the adult trauma service with rib fractures who are receiving CINB
Drug: Ropivacaine · Drug: Non steroidal anti-inflammatory drug and opioids
patients admitted to the adult trauma service with rib fractures who are receiving standard medical care
Drug: Non steroidal anti-inflammatory drug and opioids
Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.
Also known as: Naropin
Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
Length of hospital stay
time from randomization until the time of discharge
Time frame: 7 days
Patient daily pain scores
Pain will be assessed using a 10-Point Numerical Pain Scale (as part of standard of care) every day while patient is hospitalized and 2 days following discharge at follow contact. Scores range from 0-10; higher scores indicated higher levels of pain.
Time frame: 7 days
Modified Morphine Equivalent (MME) differences
Total morphine milligram equivalents (MME) will be assessed
Time frame: 7 days
hospital-free days
number of outpatient days for 1 month following randomization
Time frame: 30 days
spirometry values
measurements of inspiratory volume in milliliters will be taken pre-placement, 60 minutes after catheter insertion, the following day, and each subsequent morning
Time frame: 7 days
mean respiratory rates
number of inspiratory cycles per minute taken each day until the patient is discharged
Time frame: 7 days
Patient reported quality of life
Patient reported quality of life will be measured through the EuroQol instrument (EQ-5D-5L). The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" through "extreme problems."
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine